ChemoCentryx, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|---|---|
| Revenue | $10.4M | $6.0M | $8.3M | $42.9M | $82.5M | $11.9M |
| Operating income | −$129.9M | −$55.2M | −$58.3M | −$40.3M | $16.5M | −$40.7M |
| Net income | −$29.7M | −$21.7M | −$11.9M | −$38.0M | $17.9M | −$40.0M |
| Total assets | $425.7M | $518.9M | $209.1M | $183.3M | $189.3M | $155.9M |
| Total liabilities | $139.5M | $133.3M | $143.1M | $168.6M | $110.1M | $106.0M |
| Equity | $286.1M | $385.6M | $66.0M | $14.7M | $79.3M | $49.9M |
| EPS (diluted) | — | $-0.35 | $-0.98 | $-0.76 | $0.36 | $-0.86 |
| Shares out. | 69.6M | 61.6M | 52.6M | 48.9M | 48.2M | 44.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- −1254.9%
- Net margin
- −287.0%
- Return on equity
- −10.4%
- Return on assets
- −7.0%
- Return on capital (ROCE)
- −35.8%
- Liabilities / assets
- 32.8%
- Debt / equity
- 0.49×
- Book value / share
- $4.11
- Revenue growth (YoY)
- 72.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- -1.45distress
- Accruals / assets
- 10.8%high accruals
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- High accruals — earnings-quality risk
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- TAVNEOSOct 7, 2021
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Regulation FD disclosureOct 20, 2022
- Shareholder voteOct 18, 2022
- Other material eventSep 20, 2022
- Entered a material agreement · Regulation FD disclosureAug 4, 2022
- Director / officer change · Regulation FD disclosureJul 5, 2022
- Director / officer changeJun 9, 2022
- Director / officer change · Shareholder vote · Regulation FD disclosureJun 1, 2022
- Results of operationsMay 5, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GOct 31, 2022
- 4FORM 4 SUBMISSIONOct 24, 2022
- 4FORM 4 SUBMISSIONOct 24, 2022
- 4FORM 4 SUBMISSIONOct 24, 2022
- 4FORM 4 SUBMISSIONOct 24, 2022
- 4FORM 4 SUBMISSIONOct 24, 2022
- 4FORM 4 SUBMISSIONOct 24, 2022
- 4FORM 4 SUBMISSIONOct 24, 2022
- 4FORM 4 SUBMISSIONOct 24, 2022
- 4FORM 4 SUBMISSIONOct 24, 2022
- 4FORM 4 SUBMISSIONOct 24, 2022
- 4FORM 4 SUBMISSIONOct 24, 2022
- S-8 POSOct 20, 2022
- S-8 POSOct 20, 2022
- POSASROct 20, 2022
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.